BioDelivery Sciences submits Bunavail NDA in opioid dependence
This article was originally published in Scrip
Executive Summary
With its submission of a new drug application (NDA) for Bunavail, BioDelivery Sciences International (BDSI) is hoping to gain the FDA's approval to market the first buprenorphine/naloxone buccal film in the US as a maintenance treatment for opioid dependence opioid dependence.